Jun Morinaga, Kosuke Kashiwabara, Daisuke Torigoe, Yusuke Okadome, Kenichi Aizawa, Kohei Uemura, Ai Kurashima, Eiji Matsunaga, Hirotaka Fukami, Haruki Horiguchi, Michio Sato, Taichi Sugizaki, Keishi Miyata, Tsuyoshi Kadomatsu, Masashi Mukoyama, Katsumi Miyauchi, Seiji Hokimoto, Yoshihiro Fukumoto, Takafumi Hiro, Kiyoshi Hibi, Yoshihisa Nakagawa, Ichiro Sakuma, Yukio Ozaki, Hiroshi Iwata, Satoshi Iimuro, Hiroyuki Daida, Hiroaki Shimokawa, Takeshi Kimura, Masunori Matsuzaki, Yasushi Saito, Yutaka Matsuyama, Ryozo Nagai, Yuichi Oike
BACKGROUND: The ability to predict secondary cardiovascular events could improve health of patients undergoing statin treatment. Circulating ANGPTL8 (angiopoietin-like protein 8) levels, which positively correlate with proatherosclerotic lipid profiles, activate the pivotal proatherosclerotic factor ANGPTL3. Here, we assessed potential association between circulating ANGPTL8 levels and risk of secondary cardiovascular events in statin-treated patients. METHODS: We conducted a biomarker study with a case-cohort design, using samples from a 2018 randomized control trial known as randomized evaluation of high-dose (4 mg/day) or low-dose (1 mg/day) lipid-lowering therapy with pitavastatin in coronary artery disease (REAL-CAD [Randomized Evaluation of Aggressive or Moderate Lipid-Lowering Therapy With Pitavastatin in Coronary Artery Disease])...
June 1, 2023: Arteriosclerosis, Thrombosis, and Vascular Biology